Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Jul 06, 2024 9:26am
176 Views
Post# 36120971

RE:RE:Phase 3 run up vs ETA for 3b

RE:RE:Phase 3 run up vs ETA for 3b

"Lastly I look forward to the closure of the Vantive sale or spinoff so that Spectral can finally begin interacting with our true partner, which hopefully will include Private Equity.  July basically begins that window of when it will be finalized, but it's anybodies guess when it will be completed since Baxter has been very tight lipped about it.  Though they do have some very large bonds coming due in Novemeber and also into the foreseable future, so they have all the incentive in the world to finalize the sale of Vantive as quickly as possible." - BJ




"The parties had entered exclusive negotiations in late June, the person said, adding that a deal could be announced in the coming weeks...." -Reuters 

But of course the talks between this particular PE Firm and Baxter could still break down.

In 2016 there was only discussion of possible FDA approval. No formal distribution deal, no approved pumps or existing infrastructure for HA commercialization, no fast-tracked device approval process in place with the FDA, and no visibility on who an ultimate buyer of the NA rights might be. 

The only similarity seems to be that only a tiny fraction of the investment public is aware of this $2+ Billion USD play, incubating quietly, off- the-radar, in Canada. 

MM 

<< Previous
Bullboard Posts
Next >>